COATS (genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI) Study
Key facts
- Where
- Rotterdam, HollandiaSee the 2 sites
- Phase
- 4. fázis
Where in Hollandia
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaToborzás még nem indult
- Maasstad Ziekenhuis StichtingRotterdam, HollandiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Trial code
- EU 2024-512350-17-01
- Record updated
- 2024. szeptember 13.
- Original description
The aim of this study is to evaluate the feasibility and safety of CYP2C19-genotype-guided p2y12 inhibitor selection in patients who are indicated for (D)OAC and require PCI. Both safety and efficacy outcomes will be captured.Read full original descriptionShow less
The aim of this study is to evaluate the feasibility and safety of CYP2C19-genotype-guided p2y12 inhibitor selection in patients who are indicated for (D)OAC and require PCI. Both safety and efficacy outcomes will be captured.
Inclusion: Patients ≥ 18 years of age; Patients indicated for indefinite (D)OAC; Patients undergoing successful PCI for stable or unstable (ACS) coronary artery disease; Patients with written informed consent as approved by the ethics committee.
Exclusion: Use of gp2b3a inhibitor; Need for triple antithrombotic therapy including aspirin per treating physician; Treatment with a strong CYP3A4 inhibitor or inducer; History of definite stent thrombosis; Planned cardiac surgery; Any other condition putting patient at excessive risk for bleeding with ticagrelor; Contraindication to aspirin; Contraindication to ticagrelor or clopidogrel; Life expectancy < 1 year; Suboptimal result of stenting as defined by the operator.